The Sunday biotech signal
Phase 3 evidence lands. Sunday hiring rises.
Roche reports a Tam-Peli survival benefit while 494 active biopharma opportunities added before cutoff are 75.2% above last Sunday.
JobReports original editorial image
494
Active biopharma jobs added
27
Biopharma employers
+75.2%
Versus last Sunday
55
Manufacturing & operations
This dated issue is part of the public report archive. See the service update for account availability.
Oncology / Phase 3
Tam-Peli improves overall survival in a Phase 3 small-cell lung cancer study
Roche collaborator MediLink reported results from TAISHAN-302, a randomized Phase 3 study of Tam-Peli versus topotecan in 451 people with relapsed small-cell lung cancer across 85 sites in China. Median overall survival was 13.3 months with Tam-Peli and 9.4 months with topotecan, with a hazard ratio of 0.46 and p<0.0001.
Median progression-free survival was 7.4 months versus 2.8 months, and objective response rates were 59.1% versus 9.7%. Grade 3 or higher treatment-related adverse events occurred in 46.4% and 74.7% of patients, respectively. Roche holds development and commercialization rights outside mainland China, Hong Kong, and Macao and said it plans to initiate a global Phase 3 study rapidly.
Why it matters
The survival result adds randomized evidence for a B7-H3 antibody-drug conjugate and shifts attention toward global trial execution, regulatory planning, safety, biometrics, and oncology development. It is not an announcement of new hiring.
Sunday volume rises from last week
JobReports added 494 active biotechnology and pharmaceutical opportunities from 27 employers between midnight Eastern and today's cutoff. That is 75.2% above the 282 opportunities in the comparable Sunday window one week earlier. Manufacturing and operations was the largest named role family, followed closely by clinical and medical work.
These are active opportunities first captured by JobReports before cutoff, not employer-supplied posting times. Role-family and location classifications are directional. The hiring sample is independent of today's news announcement and does not imply Roche or MediLink created these jobs.
29
U.S. remote roles
11
Rahway, NJ roles
10
Spring House, PA roles
9
Cambridge, MA roles
Editor's shortlist
Five roles worth a closer look
Associate Scientist II, Biology
Cambridge, Massachusetts
Supervisor - Quality Assurance
Madison, Wisconsin · Onsite
Manufacturing Supervisor, Drug Product
Plainville, Massachusetts · Second shift
Senior Director, Alliance Management
New York, New York
Clinical Program Manager
Foster City or Santa Monica, CA · Parsippany, NJ
The takeaway
Randomized oncology evidence meets a broad Sunday hiring pulse.
Tam-Peli's Phase 3 results point toward global trial, regulatory, safety, biometrics, and development work without establishing new hiring. Today's independently verified openings offer a separate route into discovery biology, quality, manufacturing, alliance management, and clinical operations.